EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality
Conditions: Atrial Fibrillation; Coronary Heart Disease; Cardiovascular Diseases; Heart Failure; Hypertension; Peripheral Arterial Disease; Stroke, Ischemic; Asthma; Chronic Obstructive Pulmonary Disease; Obesity; Cancer; Chronic Kidney Diseases; Diabetes Me llitus; Dementia; Depression; Epilepsy; Mental Health Disorder; Rheumatoid Arthritis; Blood Pressure Intervention: Sponsor: Future Genetics Limited Not yet recruiting
Publication date: Available online 17 September 2019Source: Reumatología Clínica (English Edition)Author(s): Carola Baliu-Piqué, Elena Nogués-Antich, Marta Cucurell-Palomas, Dolors Grados
ConclusionsAdjustment of the cfPWV value may be necessary for a more accurate distinction between lower and higher risk group of patients for white matter microstructural injury related to arterial stiffness. Targeting the highest risk group for prevention methods may, in turn, help preserve brain health and cognitive functions.